| Literature DB >> 27213307 |
Chunhua Liu1, Aichun Ju2, Dazheng Zhou3, Dekun Li4, Junping Kou5, Boyang Yu6,7, Jin Qi8.
Abstract
YiQiFuMai injection (YQFM) is a modern lyophilized powder preparation derived from the traditional Chinese medicine Sheng-mai san (SMS) used for treating cardiovascular diseases, such as chronic heart failure. However, its chemical composition has not been fully elucidated, particularly for the preparation derived from Ophiopogon japonicus. This study aimed to establish a systematic and reliable method to quickly and simultaneously analyze the chemical constituents in YQFM by ultra-fast liquid chromatography coupled with ion trap time-of-flight mass spectrometry (UFLC-IT-TOF/MS). Sixty-five compounds in YQFM were tentatively identified by comparison with reference substances or literature data. Furthermore, twenty-one compounds, including three ophiopogonins, fifteen ginsenosides and three lignans were quantified by UFLC-IT-TOF/MS. Notably, this is the first determination of steroidal saponins from O. japonicus in YQFM. The relative standard deviations (RSDs) of intra- and inter-day precision, reproducibility and stability were <4.9% and all analytes showed good linearity (R² ≥ 0.9952) and acceptable recovery of 91.8%-104.2% (RSD ≤ 5.4%), indicating that the methods were reliable. These methods were successfully applied to quantitative analysis of ten batches of YQFM. The developed approach can provide useful and comprehensive information for quality control, further mechanistic studies in vivo and clinical application of YQFM.Entities:
Keywords: UFLC-IT-TOF/MS; YiQiFuMai injection; identification; ophiopogonins; quantification
Mesh:
Substances:
Year: 2016 PMID: 27213307 PMCID: PMC6272927 DOI: 10.3390/molecules21050640
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The base peak chromatograms (BPC) of YiQiFuMai injection by UFLC-IT-TOF/MS in negative (A) and positive ion mode (B).
Figure 2MS spectra of L-borneol-7-O-[β-d-apiofuranosyl(1→6)]-β-d-glucopyranoside, 5,2′-dihydroxy-7,8,4′-trimethoxy-6-methylhomoisoflavanone and ophiopojaponin C, and a proposed fragmentation pathway. ((A): MS1 spectrum of L-borneol-7-O-[β-d-apiofuranosyl(1→6)]-β-d-glucopyranoside under negative mode; (B): MS2 spectrum of L-borneol-7-O-[β-d-apiofuranosyl(1→6)]-β-d-glucopyranoside under negative mode; (C): MS1 spectrum of 5,2′-dihydroxy-7,8,4′-trimethoxy-6-methylhomoisoflavanone under positive mode; (D): MS2 spectra of 5,2′-dihydroxy-7,8,4′-trimethoxy-6-methylhomoisoflavanone under positive mode; (E): MS1 spectrum of ophiopojaponin C under negative mode; (F): MS2 spectra of ophiopojaponin C under negative mode; (G): MS3 spectra of ophiopojaponin C under negative mode; (H): The proposed fragmentation pathway of ophiopojaponin C under negative mode).
Figure 3The structures of the sixty-five components identified from YiQiFuMai injection.
Figure 4The extracted-ion chromatograms of 21 analytes determined by UFLC-IT-TOF/MS. ((A) & (A1): blank solution; (B) & (B1): reference solution; (C) & (C1): sample solution. 5: Re, 6: Rg1, 8: Rf, 12: S-Rg2, 13: Rb1, 14: Rh1, 17: Rc, 19: Ro, 20: Rb2, 21: Rb3, 25: ophiopojaponin C, 27: Rd, 28: ophiogenin 3-O-α-L-rhamnopyranosyl-(1→2)-β-d-glucopyranoside, 32: pennogenin-3-O-α-l-rhamnopyranosyl-(1→2)-β-d-xylopyranosyl-(1→4)-β-d-glucopyranoside, 34: schizandrol A, 38: F2, 40: gomisin D, 41: schizandrol B, 44: R-Rg3, 57: Rk1, 63: R-Rh2).
The contents of 21 compounds in 10 batches of YQFM (μg/g, mean ± SD, n = 2).
| Analyte | Y1 | Y2 | Y3 | Y4 | Y5 | Y6 | Y7 | Y8 | Y9 | Y10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Peak 25 | 10.03 ± 0.12 | 10.54 ± 0.22 | 9.26 ± 0.40 | 8.35 ± 0.26 | 9.31 ± 0.33 | 9.22 ± 0.10 | 8.94 ± 0.20 | 9.81 ± 0.12 | 9.58 ± 0.21 | 9.93 ± 0.17 |
| Peak 28 | 340.79 ± 9.34 | 338.47 ± 5.92 | 335.26 ± 14.29 | 291.53 ± 1.52 | 309.36 ± 2.44 | 316.55 ± 5.08 | 300.84 ± 4.62 | 316.60 ± 6.92 | 309.69 ± 2.47 | 337.38 ± 0.42 |
| Peak 32 | 20.53 ± 0.74 | 20.16 ± 0.12 | 18.82 ± 0.10 | 14.27 ± 0.02 | 18.44 ± 0.86 | 18.80 ± 0.26 | 17.84 ± 0.20 | 20.36 ± 0.94 | 18.34 ± 0.78 | 21.90 ± 0.02 |
| Re | 239.22 ± 4.41 | 252.46 ± 2.39 | 260.48 ± 1.60 | 258.82 ± 3.84 | 269.16 ± 1.87 | 269.12 ± 5.50 | 264.25 ± 3.79 | 260.87 ± 0.35 | 260.10 ± 3.79 | 259.90 ± 3.60 |
| Rg1 | 1655.22 ± 71.14 | 1718.39 ± 70.12 | 1763.12 ± 59.12 | 1726.97 ± 10.05 | 1822.21 ± 2.40 | 1798.42 ± 35.13 | 1744.87 ± 17.27 | 1596.24 ± 10.16 | 1646.69 ± 17.24 | 1880.85 ± 6.02 |
| Rf | 681.40 ± 15.78 | 608.42 ± 3.51 | 603.54 ± 16.76 | 751.55 ± 8.44 | 792.20 ± 38.74 | 810.92 ± 22.34 | 734.34 ± 34.89 | 809.52 ± 32.91 | 734.60 ± 33.41 | 878.60 ± 23.79 |
| Rb1 | 1862.88 ± 34.38 | 1712.90 ± 25.32 | 1410.29 ± 65.97 | 1913.08 ± 93.66 | 2111.27 ± 80.02 | 2049.96 ± 3.82 | 1929.42 ± 71.45 | 2071.68 ± 29.32 | 2077.31 ± 77.55 | 2352.52 ± 37.43 |
| S-Rg2 | 20.45 ± 0.31 | 19.60 ± 0.29 | 18.65 ± 0.16 | 20.83 ± 0.06 | 20.30 ± 0.28 | 20.53 ± 0.10 | 21.30 ± 0.85 | 20.49 ± 0.22 | 20.17 ± 0.19 | 20.65 ± 0.11 |
| Ro | 1538.77 ± 69.92 | 1474.66 ± 4.35 | 1313.99 ± 40.31 | 1615.63 ± 40.01 | 1573.38 ± 18.22 | 1632.99 ± 35.10 | 1606.87 ± 25.73 | 1657.41 ± 57.58 | 1623.26 ± 15.37 | 1673.61 ± 43.11 |
| Rh1 | 473.68 ± 10.32 | 446.74 ± 2.02 | 388.87 ± 0.19 | 452.80 ± 3.69 | 427.09 ± 2.40 | 430.71 ± 9.74 | 429.85 ± 18.48 | 434.27 ± 4.07 | 417.29 ± 2.54 | 435.27 ± 1.74 |
| Rc | 84.83 ± 2.88 | 82.08 ± 2.00 | 80.59 ± 2.03 | 75.90 ± 0.13 | 79.84 ± 2.22 | 79.33 ± 0.53 | 78.03 ± 2.13 | 81.99 ± 3.66 | 76.47 ± 0.82 | 80.25 ± 1.38 |
| Rb2 | 477.20 ± 2.00 | 459.21 ± 1.74 | 419.09 ± 9.67 | 478.33 ± 3.28 | 495.10 ± 3.62 | 509.51 ± 21.34 | 483.88 ± 13.24 | 516.15 ± 15.09 | 483.72 ± 7.12 | 521.33 ± 3.29 |
| Rb3 | 98.25 ± 4.30 | 98.91 ± 0.80 | 89.71 ± 3.43 | 97.38 ± 0.58 | 103.03 ± 3.93 | 107.85 ± 0.86 | 101.33 ± 2.40 | 103.45 ± 4.03 | 97.51 ± 1.00 | 106.48 ± 2.91 |
| Rd | 672.80 ± 2.28 | 634.78 ± 3.03 | 601.17 ± 6.81 | 750.13 ± 29.17 | 760.54 ± 5.51 | 766.45 ± 1.01 | 727.08 ± 20.25 | 732.32 ± 23.51 | 728.89 ± 14.60 | 777.63 ± 6.88 |
| F2 | 2.10 ± 0.06 | 2.12 ± 0.07 | 2.19 ± 0.05 | 2.55 ± 0.07 | 2.68 ± 0.01 | 2.78 ± 0.02 | 2.46 ± 0.07 | 2.62 ± 0.11 | 2.52 ± 0.08 | 2.77 ± 0.02 |
| R-Rg3 | 143.24 ± 3.05 | 125.54 ± 1.43 | 101.18 ± 4.62 | 142.83 ± 4.49 | 143.42 ± 2.03 | 144.29 ± 3.34 | 143.62 ± 2.96 | 155.16 ± 2.29 | 144.93 ± 1.40 | 151.46 ± 1.20 |
| Rk1 | 84.54 ± 1.54 | 72.62 ± 1.72 | 59.09 ± 3.16 | 86.94 ± 1.27 | 88.67 ± 1.98 | 88.81 ± 0.71 | 86.57 ± 1.10 | 94.12 ± 0.75 | 89.53 ± 4.26 | 94.05 ± 3.23 |
| R-Rh2 | 0.94 ± 0.04 | 0.64 ± 0.02 | 0.71 ± 0.02 | 0.87 ± 0.01 | 0.98 ± 0.02 | 0.99 ± 0.01 | 0.92 ± 0.04 | 1.06 ± 0.04 | 1.04 ± 0.03 | 0.93 ± 0.02 |
| Schizandrol A | 129.08 ± 1.90 | 132.32 ± 1.70 | 123.19 ± 4.82 | 153.32 ± 2.64 | 155.45 ± 2.93 | 150.29 ± 2.66 | 142.81 ± 3.76 | 137.67 ± 4.66 | 142.85 ± 1.92 | 147.75 ± 1.46 |
| Gomisin D | 4.39 ± 0.13 | 4.90 ± 0.14 | 4.98 ± 0.02 | 5.56 ± 0.27 | 6.03 ± 0.29 | 5.67 ± 0.05 | 5.84 ± 0.04 | 5.77 ± 0.21 | 6.10 ± 0.04 | 5.69 ± 0.14 |
| Schizandrol B | 5.83 ± 0.20 | 6.52 ± 0.28 | 6.00 ± 0.25 | 7.03 ± 0.18 | 6.37 ± 0.10 | 6.82 ± 0.21 | 6.68 ± 0.32 | 6.55 ± 0.18 | 6.42 ± 0.22 | 6.31 ± 0.10 |
Note: Peak 25: ophiopojaponin C; Peak 28: ophiogenin 3-O-α-l-rhamnopyranosyl-(1→2)-β-d-glucopyranoside; Peak 32: pennogenin-3-O-α-l-rhamnopyranosyl-(1→2)-β-d-xylopyranosyl-(1→4)-β-d-glucopyranoside.